February 12, 2018 / 1:15 PM / 5 months ago

BRIEF-Daré Bioscience Enters Into Agreement To License SST-6007, A Potential Treatment For FSAD

Feb 12 (Reuters) - Dare Bioscience Inc:

* DARÉ BIOSCIENCE, INC. ENTERS INTO LICENSE AND COLLABORATION AGREEMENT FOR A PRODUCT WITH THE POTENTIAL TO RECEIVE THE FIRST FDA APPROVAL FOR FEMALE SEXUAL AROUSAL DISORDER

* DARE BIOSCIENCE INC - ‍ENTERED INTO AN AGREEMENT TO LICENSE SST-6007​

* DARE BIOSCIENCE INC - ‍DARÉ ANTICIPATES COMMENCING A PHASE 2B CLINICAL TRIAL IN SECOND HALF OF 2018 FOR SST-6007​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below